The company plans to import phenylacetone (8501), and poppy straw concentrate (9670) to bulk manufacture other controlled substances for distribution to its customers. The company plans to import an intermediate form of tapentadol (9780) to bulk manufacture tapentadol (9780) for distribution to its customers.

The company plans to import impurities of buprenorphine that have been determined by DEA to be captured under drug code (9333) thebaine.

In reference to drug codes 7360 and 7370, the company plans to import a synthetic cannabinoid and a synthetic tetrahydrocannabinol. No other activity for these drug codes is authorized for this registration. Placement of these drug codes onto the company’s registration does not translate into automatic approval of subsequent permit applications to import controlled substances. Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of FDA approved or non-approved finished dosage forms for commercial sale.

Dated: October 10, 2018.

John J. Martin,
Assistant Administrator.

[FR Doc. 2018–22832 Filed 10–18–18; 8:45 am]
BILLING CODE 4410–09–P

### DEPARTMENT OF JUSTICE

**Drug Enforcement Administration**

[Docket No. DEA–392]

**Importer of Controlled Substances Application: Fisher Clinical Services, Inc.**

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before November 19, 2018. Such persons may also file a written request for a hearing on the application on or before November 19, 2018.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

In accordance with 21 CFR 1301.34(a), this notice that on June 4, 2018, Fisher Clinical Services, Inc., 7554 Schantz Road, Allentown, Pennsylvania 18106 applied to be registered as an importer of the following basic class of controlled substance:

<table>
<thead>
<tr>
<th>Controlled Substance</th>
<th>Drug code</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psilocybin</td>
<td>7437</td>
<td>I</td>
</tr>
</tbody>
</table>

Dated: October 10, 2018.

John J. Martin,
Assistant Administrator.

[FR Doc. 2018–22832 Filed 10–18–18; 8:45 am]
BILLING CODE 4410–09–P

### DEPARTMENT OF JUSTICE

**[OMB Number 1121–0184]**

**Agency Information Collection Activities; Proposed eCollection eComments Requested; Revision of a Currently Approved Collection; Comments Requested: 2019 School Crime Supplement (SCS) to the National Crime Victimization Survey (NCVS)**

**AGENCY:** Bureau of Justice Statistics, Department of Justice.

**ACTION:** 30-Day notice.

**SUMMARY:** The Department of Justice (DOJ), Office of Justice Programs, Bureau of Justice Statistics, will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.

**DATES:** Comments are encouraged and will be accepted for 30 days until November 19, 2018.

**FOR FURTHER INFORMATION CONTACT:** If you have additional comments especially on the estimated public burden or associated response time,